I treat people whose illnesses don’t resolve in a few visits. Many of my patients have depression that hasn’t responded to several medications, or OCD that has shaped their lives for decades. Getting them better takes time, and it takes knowing them well. So I’ve watched with some unease as mental health care has become a favorite target for investors. I should say up front that I own a small independent psychiatry practice and now compete with several groups backed by private equity, so I have a stake in this. I’ve tried to let the evidence carry the argument.
By 2022, about 6.2 percent of U.S. mental health facilities were owned by private equity, and the buying has since spread to psychiatric hospitals. The playbook is no secret. A firm buys a practice, loads it with debt, cuts costs, pushes revenue, and plans to sell within a few years, usually fewer than seven. Capital can do real good. It can pay for better information systems, make recruiting easier, and keep a struggling practice from closing. My concern is timing. Someone with bipolar disorder, treatment-resistant depression, or early psychosis needs care measured in years, while a fund’s exit strategy is measured in quarters. Patients and families deserve to know which of those two clocks their care runs on.
The research we have so far should make all of us cautious. A systematic review of 55 studies in the BMJ found that private equity ownership was most consistently tied to higher costs for patients and payers, with mixed to harmful effects on quality and no consistent benefit. Hospitals acquired by private equity saw a 25 percent relative increase in preventable hospital-acquired conditions compared with matched hospitals.
We have much less data specific to psychiatry. Part of the reason is that many acquisitions don’t have to be disclosed, and nondisclosure agreements are common. To me, that gap is a reason to look harder. Psychiatric patients are vulnerable, and they are often cared for in settings where outsiders can see very little and patients have few choices. In a 2026 position paper, the American College of Physicians urged policymakers to protect clinical autonomy and to make sure physicians keep control over patient care.
Real physician voices, twice a week
Free, and one click to unsubscribe.
When doctors talk about autonomy, it can sound like we’re protecting our turf. I understand that reaction. But in my experience, autonomy is how a patient’s needs actually make it into the exam room. It means the psychiatrist who knows the patient decides whether a medication change calls for a full hour or a quick fifteen minutes, whether a stable patient can safely come in less often, and whether a crisis is worth clearing the afternoon for.
Productivity models built on billable units and session counts are easy to track. They also tend to miss the quality of care, and they have been linked to clinician burnout, turnover, and pressure toward ethically questionable practices. Physicians employed by organizations that private equity has acquired report lower satisfaction and less autonomy, and they are less likely to stay with their employer. In many fields, turnover is mostly a staffing problem. In psychiatry, when a doctor leaves, the patient loses the therapeutic relationship too.
That relationship is the treatment. Continuity of care has long been considered essential for people with serious mental illness. It has been associated with better social functioning, quality of life, and symptom control, although study methods vary. When you ask patients with long-term mental illness what they value most, they keep giving the same answer, and it’s continuity.
Care built to scale depends on protocolized visits, rotating clinicians, and handing work to whoever costs least. On a spreadsheet that can look efficient. In the room, it slowly wears away the knowledge that keeps patients safe: what this person’s last relapse looked like, which side effect nearly made them stop treatment, and what “I’m fine” really means when they say it. Data from the Veterans Health Administration point the same way. Adequate staffing predicted better mental health treatment quality, access, continuity, and satisfaction more strongly than productivity metrics did.
I’m not claiming that every practice backed by investors does harm, or that every independent practice is excellent. Ownership doesn’t decide outcomes by itself. Incentives do shape them, and patients have every right to ask about those incentives.
I don’t support psychiatry led by physicians out of nostalgia. I support it because it leaves decisions with the person who is accountable for how the patient does. In a field where the relationship does so much of the healing, that arrangement is worth defending.
Ravi Singareddy is the founder and medical director of Empower Psychiatry & Sleep in north metro Atlanta, where he leads an interventional psychiatry practice offering transcranial magnetic stimulation (TMS) and Spravato (esketamine) for treatment-resistant depression. Double board-certified in psychiatry and sleep medicine, he brings more than two decades of clinical and academic experience to patients who haven’t found relief with medications alone. He is affiliated with Emory Healthcare.
His interest in neuromodulation dates back to his years as associate professor of psychiatry at Penn State College of Medicine. There, he taught annually on vagus nerve stimulation and novel depression therapies, and he published on long-term combined electroconvulsive therapy and vagus nerve stimulation in the American Journal of Psychiatry. He has authored numerous peer-reviewed papers on sleep disorders, insomnia, anxiety, and depression, with work appearing in Sleep, the Journal of Clinical Sleep Medicine, and Psychiatry Research.
Singareddy is a Fellow of the American Psychiatric Association and the American Academy of Sleep Medicine and practices measurement-based care, tracking outcomes to guide every treatment decision. He shares updates on Instagram.



